GLP-1s and fertility or pregnancy: current guidance

GLP-1s sit at the intersection of two things that matter enormously for fertility: weight and hormone regulation. That makes this a genuinely nuanced topic, with real emerging evidence on the fertility side and real caution on the pregnancy side. Here's where things currently stand.

The fertility side: why weight loss alone can restore ovulation

For people with obesity-related ovulatory dysfunction, meaningful weight loss can restore regular ovulation on its own, independent of any drug-specific hormonal effect — which is part of why GLP-1-driven weight loss has drawn real interest as a fertility intervention rather than only a metabolic one¹. A review focused specifically on reproductive-age women found evidence supporting the idea that GLP-1 receptor agonists can help restore fertility in appropriate candidates, largely through this weight and metabolic pathway⁶. There's also emerging, more mechanistic research looking at direct effects on endometrial receptivity and implantation, an active and still-developing area rather than settled science⁵. None of this makes a GLP-1 a fertility treatment in the way a reproductive endocrinologist would use that term — it's a metabolic intervention with a documented fertility-adjacent effect in the right candidates.

Why you can't be on one during pregnancy

This is the clearest, least ambiguous part of the guidance: GLP-1s are not recommended during pregnancy. A clinical review of GLP-1 receptor agonist use in pregnancy describes the current evidence as insufficient to establish safety, and current guidance is to discontinue before a planned pregnancy². A broader systematic review of maternal, fetal, and neonatal outcomes across preconception, pregnancy, and lactation exposure similarly found the evidence base still developing, without the kind of large, controlled safety data available for many other medication classes used in pregnancy³. Human pregnancy-outcome data is accumulating — a Danish nationwide cohort study of periconceptional GLP-1 exposure and obstetric outcomes is one recent example — but this remains an active research area, not a settled safety profile⁴.

What 'stop before you try to conceive' actually means in practice

Guidance in this space generally points toward discontinuing a GLP-1 before actively trying to conceive, with the specific timing best set by your prescriber based on the medication's clearance and your individual situation rather than a fixed number you should assume applies to everyone. This is also where the regain risk of stopping a GLP-1 becomes directly relevant to family planning, not just weight maintenance — it's worth discussing both the timing of stopping and a plan for the metabolic and weight changes that may follow, ideally with both your prescribing clinician and your OB or fertility specialist involved.

If you become pregnant while on one

If you find out you're pregnant while taking a GLP-1, the standard, responsible step is to stop the medication and contact your prescriber and OB promptly rather than making an independent decision about what it means — this is exactly the kind of situation where the evidence gaps described above make individualized clinical guidance more important than a general article, not less. Case-series data on pregnancies with GLP-1 exposure exists and is being collected precisely because larger, controlled data isn't yet available².

Related considerations

If PCOS is part of your picture, GLP-1 for PCOS covers the evidence on that specific overlap between metabolic treatment and reproductive health. This is general information about a genuinely evolving evidence base, not medical advice for your specific pregnancy plans — a reproductive endocrinologist or your OB, working alongside your prescriber, is the right team for those decisions.